Can a Self-Amplifying RNA vaccine outsmart the latest COVID variant?
Vaccine
Not yet recruiting
This early-stage trial tests a new vaccine called BMI2012, designed to protect against the Omicron JN.1 variant of COVID-19. Healthy adults aged 19 to 55 receive a single injection of either the vaccine or a placebo. Researchers will check how safe the vaccine is and whether it t…
Phase 1 • Sponsor: BMI Korea • Aim: Vaccine
Last updated Aug 30, 2026 00:00 UTC